Features and properties of drug name

Alternative names	Adtralza; CAT-354; LP-0162
Class	Anti-inflammatories; Antiasthmatics; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
Mechanism of action	Interleukin 13 inhibitors
Route of administration	Subcutaneous injection
Pharmacodynamics	Specifically inhibits the interaction of IL-13 with the IL-13Rα1/IL-4Rα receptor complex, neutralising the biological activity of IL-13
Pharmacokinetics	Median time to tmax 5-8 days after a single dose; reaches steady-state pharmacokinetics by 16 weeks; estimated absolute bioavailability of 76%; estimated total volume of distribution is ~4.2 L; clearance rate 0.149 L/day; elimination half-life of 22 days
Most common adverse reactions	Upper respiratory tract infections (mainly reported as common cold), injection site reactions, conjunctivitis, allergic conjunctivitis
ATC codes
WHO ATC code	D11A-H07 (Tralokinumab); D11A-X (Other dermatologicals); R (Respiratory System)
EphMRA ATC code	D11A (Other Dermatological Preparations); D5 (Nonsteroidal Products for Inflammatory Skin Disorders); R (Respiratory System)
Chemical name	Immunoglobulin G4, anti-(human interleukin 13) (human monoclonal CAT-354 heavy chain), disulfide with human monoclonal CAT-354 light chain, dimer